Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

256 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No evidence of disease activity in patients receiving fingolimod at private or academic centers in clinical practice: a retrospective analysis of the multiple sclerosis, clinical, and magnetic resonance imaging outcomes in the USA (MS-MRIUS) study.
Zivadinov R, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Kolodny S, Silva D, Medin J, Weinstock-Guttman B; MS-MRIUS study group. Zivadinov R, et al. Among authors: medin j. Curr Med Res Opin. 2018 Aug;34(8):1431-1440. doi: 10.1080/03007995.2018.1458708. Epub 2018 Apr 12. Curr Med Res Opin. 2018. PMID: 29648900
Feasibility of Brain Atrophy Measurement in Clinical Routine without Prior Standardization of the MRI Protocol: Results from MS-MRIUS, a Longitudinal Observational, Multicenter Real-World Outcome Study in Patients with Relapsing-Remitting MS.
Zivadinov R, Bergsland N, Korn JR, Dwyer MG, Khan N, Medin J, Price JC, Weinstock-Guttman B, Silva D; MS-MRIUS Study Group. Zivadinov R, et al. Among authors: medin j. AJNR Am J Neuroradiol. 2018 Feb;39(2):289-295. doi: 10.3174/ajnr.A5442. Epub 2017 Nov 23. AJNR Am J Neuroradiol. 2018. PMID: 29170269 Free PMC article.
Assessing 'No Evidence of Disease Activity' Status in Patients with Relapsing-Remitting Multiple Sclerosis Receiving Fingolimod in Routine Clinical Practice: A Retrospective Analysis of the Multiple Sclerosis Clinical and Magnetic Resonance Imaging Outcomes in the USA (MS-MRIUS) Study.
Weinstock-Guttman B, Medin J, Khan N, Korn JR, Lathi E, Silversteen J, Calkwood J, Silva D, Zivadinov R; MS-MRIUS Study Group. Weinstock-Guttman B, et al. Among authors: medin j. CNS Drugs. 2018 Jan;32(1):75-84. doi: 10.1007/s40263-017-0482-4. CNS Drugs. 2018. PMID: 29270772 Free PMC article.
Fingolimod's Impact on MRI Brain Volume Measures in Multiple Sclerosis: Results from MS-MRIUS.
Zivadinov R, Medin J, Khan N, Korn JR, Bergsland N, Dwyer MG, Chitnis T, Naismith RT, Alvarez E, Kinkel P, Cohan S, Hunter SF, Silva D, Weinstock-Guttman B; MS-MRIUS investigators. Zivadinov R, et al. Among authors: medin j. J Neuroimaging. 2018 Jul;28(4):399-405. doi: 10.1111/jon.12518. Epub 2018 May 11. J Neuroimaging. 2018. PMID: 29749661
Impact of fingolimod on clinical and magnetic resonance imaging outcomes in routine clinical practice: A retrospective analysis of the multiple sclerosis, clinical and MRI outcomes in the USA (MS-MRIUS) study.
Zivadinov R, Medin J, Khan N, Korn JR, Chitnis T, Naismith RT, Alvarez E, Dwyer MG, Bergsland N, Carl E, Silva D, Weinstock-Guttman B; MS-MRIUS Study Group. Zivadinov R, et al. Among authors: medin j. Mult Scler Relat Disord. 2019 Jan;27:65-73. doi: 10.1016/j.msard.2018.09.037. Epub 2018 Oct 3. Mult Scler Relat Disord. 2019. PMID: 30342416
Establishing pathological cut-offs for lateral ventricular volume expansion rates.
Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R. Dwyer MG, et al. Among authors: medin j. Neuroimage Clin. 2018 Feb 7;18:494-501. doi: 10.1016/j.nicl.2018.02.009. eCollection 2018. Neuroimage Clin. 2018. PMID: 29527505 Free PMC article.
Linked Patient-Reported Outcomes Data From Patients With Multiple Sclerosis Recruited on an Open Internet Platform to Health Care Claims Databases Identifies a Representative Population for Real-Life Data Analysis in Multiple Sclerosis.
Risson V, Ghodge B, Bonzani IC, Korn JR, Medin J, Saraykar T, Sengupta S, Saini D, Olson M. Risson V, et al. Among authors: medin j. J Med Internet Res. 2016 Sep 22;18(9):e249. doi: 10.2196/jmir.5805. J Med Internet Res. 2016. PMID: 27658498 Free PMC article.
Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the Benefit-Risk Profile of Fingolimod After 1 Year of Treatment: Initial Results From the Observational, Noninterventional Study PANGAEA.
Ziemssen T, Lang M, Tackenberg B, Schmidt S, Albrecht H, Klotz L, Haas J, Lassek C, Medin J, Cornelissen C; PANGAEA study group. Ziemssen T, et al. Among authors: medin j. Neurotherapeutics. 2018 Jan;15(1):190-199. doi: 10.1007/s13311-017-0595-y. Neurotherapeutics. 2018. PMID: 29274026 Free PMC article.
256 results